Product Description
voltage-gated calcium channel blockers for neuropathic pain
Mechanisms of Action: N-type Calcium Channel Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Convergence
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Peripheral Nervous System Diseases|Neuralgia, Postherpetic|Neuralgia|Neuropathic Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2013-000407-16 | P2 |
Completed |
Neuropathic Pain |
2014-06-30 |
2022-03-13 |
Treatments |
|
| CNV2197944/202 | P2 |
Completed |
Peripheral Nervous System Diseases |
2014-06-01 |
2019-03-19 |
Treatments |
|
| 2012-002903-16 | P2 |
Completed |
Neuralgia |
2014-02-06 |
2025-06-14 |
Treatments |
|
| CNV2197944/201 | P2 |
Completed |
Neuralgia, Postherpetic |
2014-02-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|